Covaxin has already been granted Emergency Use Listing (EUL) in 13 countries as on January 31 according to the WHO. Covaxin was granted EUL...

“WHO has a technical advisory group made up of independent experts who assess COVID19 vaccines. The process relies on manufacturers to prov...

WHO's TAG is an independent advisory group that provides recommendations to the WHO on whether a Covid 19 vaccine can be listed for emergen...

Hyderabad-based Bharat Biotech, which has developed Covaxin, submitted EOI (Expression of Interest) to the WHO on April 19 for the vaccine'...

"The TAG met today (26 October 2021) and decided that additional clarifications from the manufacturer are needed to conduct a final EUL ris...

WHO had earlier said that Bharat Biotech has been submitting data to it on a rolling basis and had submitted additional information on 27 S...

The latest 'Status of COVID-19 vaccines within WHO EUL/PQ evaluation process' guidance document dated September 29 on the WHO website said ...

The sources further said that the UN public health agency has asked for more data from Bharat Biotech for Covaxin. This delay will affect I...

“The Coordination of Clinical Research at Anvisa (Copec/GGMED) determined this Friday (23/7) the precautionary suspension of clinical studi...

Under the agreement, Ocugen will have the US rights to the vaccine candidate and will be responsible for clinical development, regulatory a...

Unlike China, India is not pursuing an aggressive policy to get Covaxin approved but rather a quiet diplomacy, advising Bharat Biotech on n...

Announcing the much awaited safety and efficacy data from phase-3 clinical trials of Covaxin, the IMCR director Prof Balram Bhargava said C...

According to the Centre's affidavit, over 1.8 million doses of Covaxin are pending against its order for 20 million doses in March.

The Indian biotech company and Ocugen Inc have entered into a definitive agreement to co-develop, supply, and commercialise Covaxin for the...

“The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production ...

"COVAXIN clinical trials are based on a two-dose schedule, given 28 days apart. The vaccine efficacy will be determined 14 days after the s...

"This is India's first phase-III efficacy study for a Covid-19 vaccine, and the largest phase-III efficacy trial ever conducted in India," ...